Total Payments
$312,281
2024 Payments
$91,870
Companies
96
Transactions
1,574
Medicare Patients
2,191
Medicare Billing
$502,961
Payment Breakdown by Category
Other$185,483 (59.4%)
Travel$53,506 (17.1%)
Consulting$41,632 (13.3%)
Food & Beverage$30,397 (9.7%)
Education$1,263 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $107,938 | 35 | 34.6% |
| Honoraria | $76,614 | 24 | 24.5% |
| Travel and Lodging | $53,506 | 201 | 17.1% |
| Consulting Fee | $41,632 | 17 | 13.3% |
| Food and Beverage | $30,397 | 1,265 | 9.7% |
| Education | $1,263 | 22 | 0.4% |
| Long term medical supply or device loan | $931.52 | 10 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $137,347 | 209 | $0 (2024) |
| Pharmacosmos Therapeutics Inc. | $107,287 | 179 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $19,639 | 59 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $9,585 | 62 | $0 (2024) |
| SOBI, INC | $5,127 | 17 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $3,850 | 4 | $0 (2024) |
| PharmaEssentia USA Corporation | $3,339 | 7 | $0 (2024) |
| ABBVIE INC. | $2,683 | 27 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $1,880 | 64 | $0 (2024) |
| Janssen Biotech, Inc. | $1,641 | 86 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $91,870 | 416 | Pharmacosmos Therapeutics Inc. ($57,921) |
| 2023 | $57,230 | 206 | Incyte Corporation ($24,947) |
| 2022 | $68,470 | 309 | Pharmacosmos Therapeutics Inc. ($24,382) |
| 2021 | $30,432 | 175 | Incyte Corporation ($23,760) |
| 2020 | $30,619 | 151 | Incyte Corporation ($24,201) |
| 2019 | $30,444 | 170 | Incyte Corporation ($22,261) |
| 2018 | $1,847 | 85 | PFIZER INC. ($271.00) |
| 2017 | $1,369 | 62 | PFIZER INC. ($270.16) |
All Payment Transactions
1,574 individual payment records from CMS Open Payments — Page 1 of 63
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $23.87 | General |
| 12/18/2024 | Incyte Corporation | JAKAFI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $5,500.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/17/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $70.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/17/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $31.55 | General |
| Category: ONCOLOGY | ||||||
| 12/16/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $29.17 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Blueprint Medicines Corporation | AYVAKIT (Drug) | Food and Beverage | Cash or cash equivalent | $27.98 | General |
| Category: Oncology / Rare Diseases | ||||||
| 12/13/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $10.49 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $660.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | Truqap (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $378.97 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $199.38 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $124.98 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $33.50 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Food and Beverage | Cash or cash equivalent | $17.61 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/12/2024 | Incyte Corporation | JAKAFI (Drug) | Travel and Lodging | Cash or cash equivalent | $8.00 | General |
| Category: Hematology/Oncology | ||||||
| 12/11/2024 | Janssen Biotech, Inc. | CARVYKTI (Drug) | Food and Beverage | In-kind items and services | $27.65 | General |
| Category: Oncology | ||||||
| 12/11/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $11.92 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Eisai Inc. | Lenvima (Drug) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Oncology | ||||||
| 12/10/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $0.16 | General |
| Category: ONCOLOGY | ||||||
| 12/09/2024 | PUMA BIOTECHNOLOGY, INC. | — | Food and Beverage | In-kind items and services | $25.29 | General |
| 12/09/2024 | GlaxoSmithKline, LLC. | OJJAARA (Drug) | Food and Beverage | In-kind items and services | $11.43 | General |
| Category: ONCOLOGY | ||||||
| 12/06/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: HORMONE THERAPY | ||||||
| 12/05/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $20.62 | General |
| Category: ONCOLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $18.43 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 349 | 3,011 | $178,809 | $57,399 |
| 2022 | 19 | 610 | 9,245 | $419,188 | $152,135 |
| 2021 | 16 | 577 | 6,798 | $406,299 | $155,982 |
| 2020 | 20 | 655 | 7,111 | $434,034 | $137,445 |
Total Patients
2,191
Total Services
26,165
Medicare Billing
$502,961
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 14 | 1,320 | $65,900 | $23,569 | 35.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 44 | 115 | $32,359 | $10,342 | 32.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 18 | 62 | $22,656 | $6,271 | 27.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 72 | 93 | $19,276 | $5,363 | 27.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $9,485 | $2,600 | 27.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 12 | 15 | $6,720 | $2,116 | 31.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $5,072 | $1,444 | 28.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 20 | 111 | $4,453 | $1,306 | 29.3% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 19 | 24 | $4,087 | $1,150 | 28.1% |
| 36591 | Collection of blood sample from implanted device | Office | 2023 | 17 | 46 | $2,768 | $896.44 | 32.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 29 | 82 | $2,588 | $854.60 | 33.0% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 12 | 12 | $2,502 | $795.00 | 31.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 36 | 89 | $570.84 | $558.60 | 97.9% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 15 | 960 | $243.80 | $90.48 | 37.1% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 15 | 56 | $130.38 | $44.44 | 34.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 27 | 4,080 | $177,073 | $69,971 | 39.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 338 | $96,130 | $32,635 | 33.9% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 21 | 157 | $50,899 | $16,717 | 32.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 104 | 161 | $32,503 | $10,761 | 33.1% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 22 | 23 | $9,752 | $3,592 | 36.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 23 | 23 | $8,457 | $3,052 | 36.1% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2022 | 30 | 212 | $7,836 | $2,663 | 34.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 15 | 18 | $7,200 | $2,567 | 35.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2022 | 13 | 44 | $7,040 | $2,269 | 32.2% |
| 36591 | Collection of blood sample from implanted device | Office | 2022 | 21 | 101 | $6,461 | $2,007 | 31.1% |
About Christopher Chen, MD, MBA
Christopher Chen, MD, MBA is a Hematology & Oncology healthcare provider based in Tucson, Arizona. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/09/2010. The National Provider Identifier (NPI) number assigned to this provider is 1851603674.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christopher Chen, MD, MBA has received a total of $312,281 in payments from pharmaceutical and medical device companies, with $91,870 received in 2024. These payments were reported across 1,574 transactions from 96 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($107,938).
As a Medicare-enrolled provider, Chen has provided services to 2,191 Medicare beneficiaries, totaling 26,165 services with total Medicare billing of $502,961. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology, Hematology & Oncology
- Location Tucson, AZ
- Active Since 07/09/2010
- Last Updated 11/13/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1851603674
Products in Payments
- JAKAFI (Drug) $130,493
- MONOFERRIC (Drug) $104,887
- Nubeqa (Drug) $19,303
- IMFINZI (Biological) $6,163
- DOPTELET (Drug) $5,057
- LIBTAYO (Biological) $4,088
- BESREMI (Drug) $3,339
- VENCLEXTA (Drug) $2,485
- Monoferric (Drug) $2,400
- KEYTRUDA (Biological) $1,281
- KISQALI (Drug) $950.07
- DARZALEX (Biological) $703.63
- IMBRUVICA (Drug) $683.31
- BRUKINSA (Drug) $678.41
- XTANDI (Drug) $675.62
- OPDIVO (Biological) $537.79
- ADCETRIS (Biological) $526.18
- Truqap (Drug) $525.00
- JEVTANA (Drug) $415.19
- Revlimid (Drug) $407.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Tucson
Dr. Rachna Shroff, Md, MD
Hematology & Oncology — Payments: $257,150
Hematology & Oncology $257,150
Alison Stopeck, Md, MD
Hematology & Oncology — Payments: $240,782
Hematology & Oncology $240,782
Michael Boxer, M.d, M.D
Hematology & Oncology — Payments: $86,711
Hematology & Oncology $86,711
Dr. Rachel Swart, M.d.,Ph.d, M.D.,PH.D
Hematology & Oncology — Payments: $69,563
Hematology & Oncology $69,563
Sudhir Manda, Md, MD
Hematology & Oncology — Payments: $50,979
Hematology & Oncology $50,979
Basel Shoua, M.d, M.D
Hematology & Oncology — Payments: $45,611
Hematology & Oncology $45,611